Takeda Pharmaceutical Company Limited (NYSE: TAK) is 4.62% higher on its value in year-to-date trading and has touched a low of $12.28 and a high of $17.15 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TAK stock was last observed hovering at around $16.42 in the last trading session, with the day’s loss setting it -0.1% off its average median price target of $17.53 for the next 12 months. It is also 21.12% off the consensus price target high of $20.69 offered by 18 analysts, but current levels are -19.39% lower than the price target low of $13.67 for the same period.
Currently trading at $16.32, the stock is -1.77% and -1.43% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.64 million and changing -0.61% at the moment leaves the stock 8.98% off its SMA200. TAK registered 10.87% gain for a year compared to 6-month gain of 15.74%. The firm has a 50-day simple moving average (SMA 50) of $0.02 and a 200-day simple moving average (SMA200) of $0.06.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The stock witnessed a -3.20% loss in the last 1 month and extending the period to 3 months gives it a 3.49%, and is -0.79% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.78% over the week and 0.93% over the month.
Takeda Pharmaceutical Company Limited (TAK) has around 47347 employees, a market worth around $51.77B and $29.04B in sales. Current P/E ratio is 22.36. Profit margin for the company is 7.90%. Distance from 52-week low is 32.90% and -4.84% from its 52-week high. The company has generated returns on investments over the last 12 months (4.00%).
Takeda Pharmaceutical Company Limited (TAK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Takeda Pharmaceutical Company Limited (TAK) is a “Overweight”. 18 analysts offering their recommendations for the stock have an average rating of 2.00, where 9 rate it as a Hold and 1 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Takeda Pharmaceutical Company Limited is expected to release its quarterly report on 07/27/2023.The EPS is expected to grow by 38.40% this year.
Takeda Pharmaceutical Company Limited (TAK) Top Institutional Holders
The shares outstanding are 3.11B, and float is at 3.11B with Short Float at 0.19%.
Takeda Pharmaceutical Company Limited (TAK): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -11.40% down over the past 12 months and Sanofi (SNY) that is 0.52% higher over the same period. Pfizer Inc. (PFE) is -24.45% down on the 1-year trading charts.